keyword
MENU ▼
Read by QxMD icon Read
search

Cachexia-anorexia cancer

keyword
https://www.readbyqxmd.com/read/29047408/the-efficacy-of-the-kampo-medicine-rikkunshito-for-chemotherapy-induced-anorexia-rich-trial-study-protocol-for-a-randomized-controlled-trial
#1
Takuya Inoue, Hironori Takagi, Yuki Owada, Yuzuru Watanabe, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroshi Yokouchi, Kenya Kanazawa, Katsuya Ohbuchi, Takahisa Fukushima, Mitsuru Munakata, Hiroyuki Suzuki
BACKGROUND: Cisplatin is a key drug in lung cancer therapy. However, cisplatin is also well known to induce gastrointestinal disorders, such as chemotherapy-induced nausea and vomiting, anorexia, and weight loss. These symptoms sometimes affect patients' quality of life and make continuation of chemotherapy difficult. Anorexia is a cause of concern for patients with cancer because a persistent loss of appetite progresses to cancer cachexia. Although evidence-based management for chemotherapy has recently been established, there is room for improvement...
October 18, 2017: Trials
https://www.readbyqxmd.com/read/29027398/nutritional-status-cachexia-and-anorexia-in-women-with-peritoneal-metastasis-and-intraperitoneal-chemotherapy-a-longitudinal-analysis
#2
Ziad Hilal, Günther A Rezniczek, Robert Klenke, Askin Dogan, Clemens B Tempfer
OBJECTIVE: To describe the nutritional status of women with peritoneal metastasis (PM) from recurrent ovarian, fallopian, or peritoneal cancer and to assess longitudinal variations of the cachexia-anorexia syndrome (CAS) during palliative pressurized intraperitoneal aerosol chemotherapy (PIPAC). METHODS: Nutritional assessment included body mass index (BMI), bioelectrical impedance analysis (BIA), and blood chemistry. CAS presence/absence was recorded before and during repeated cycles (1-11) of PIPAC...
November 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/29019951/chemotherapy-related-toxicity-nutritional-status-and-quality-of-life-in-precachectic-oncologic-patients-with-or-without-high-protein-nutritional-support-a-prospective-randomized-study
#3
Monika Ziętarska, Joanna Krawczyk-Lipiec, Leszek Kraj, Renata Zaucha, Sylwia Małgorzewicz
BACKGROUND: Cancer disease is usually associated with impaired nutritional status, which is one of the factors contributing to deterioration of the results of surgery, chemotherapy or radiotherapy. OBJECTIVES: The aim of the study was to determine whether nutritional support with high protein (ONS) in adult oncologic patients in the first step of cancer cachexia-asymptomatic precachexia, has an influence on the toxicity of systemic therapy. However, secondary endpoints were established: to determine whether high protein ONS influences the nutritional status, the quality of life, and the performance status...
October 11, 2017: Nutrients
https://www.readbyqxmd.com/read/28957883/what-is-next-after-anamorelin
#4
Jose M Garcia
PURPOSE OF REVIEW: In spite of its relevance, treatments for the cancer anorexia and cachexia syndrome (CACS) are not available. One of the agents that recently reached phase III clinical trials is anamorelin. Its development, along with that of other agents for this indication, will be reviewed here, with a focus on the gaps in the current knowledge and future directions. RECENT FINDINGS: In spite of several targets showing promising results in early development, their difficulties obtaining regulatory approval underscore the need to reconsider the current strategies in drug development and the challenges in the field of CACS...
September 27, 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28948436/mapping-health-related-quality-of-life-scores-from-fact-g-faact-and-facit-f-onto-preference-based-eq-5d-5l-utilities-in-non-small-cell-lung-cancer-cachexia
#5
Michela Meregaglia, Ludovica Borsoi, John Cairns, Rosanna Tarricone
BACKGROUND: Health-related quality of life (HRQoL) measurements from disease-specific tools cannot be directly used in economic evaluations. This study aimed to develop and validate mapping algorithms that predicted EuroQol 5-Dimensions 5-Levels (EQ-5D-5L) utilities from Functional Assessment of Anorexia-Cachexia Therapy (FAACT) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) and their common component (Functional Assessment of Cancer Therapy-General-FACT-G) in patients with non-small cell lung cancer cachexia...
September 25, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28883883/atractylodin-induces-myosin-light-chain-phosphorylation-and-promotes-gastric-emptying-through-ghrelin-receptor
#6
Yu Bai, Yan-Hua Zhao, Jian-Ya Xu, Xi-Zhong Yu, Yun-Xia Hu, Zhi-Qiang Zhao
Atractylodin is one of the main constituents in the rhizomes of Atractylodes lancea Thunb., being capable of treating cancer cachexia-anorexia and age-related diseases as an agonist of growth hormone secretagogue receptor (GHSR). GHSR was herein expressed in human gastric smooth muscle cells (HGSMCs) and activated by ghrelin receptor agonist L-692,585. Like L-692,585, atractylodin also increased Ca(2+) and enhanced the phosphorylation of myosin light chain (MLC) through GHSR in HGSMCs. In addition, atractylodin promoted gastric emptying and MLC phosphorylation in the gastric antrum of mice also through GHSR...
2017: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/28858429/energy-imbalance-and-cancer-cause-or-consequence
#7
REVIEW
Xiaohui Wang, Wei Liu, Xiangyang Xie
Obesity has been an epidemic worldwide over the past decades and significantly increases the risk of developing a variety of deadly diseases including type 2 diabetes, cardiovascular diseases and many cancers. The relationship between obesity and type 2 diabetes and cardiovascular disease has been well documented. The drastically increased frequency of a number of cancers in obesity has attracted growing interest. On one hand, how increased adiposity promotes cancer development remains poorly understood, despite the fact that considerable epidemiological evidence has suggested links between them...
October 2017: IUBMB Life
https://www.readbyqxmd.com/read/28855797/oncology-update-anamorelin
#8
REVIEW
Eric Prommer
BACKGROUND: Cancer cachexia is a catabolic syndrome associated with uncontrolled muscle breakdown. There may be associated fat loss. Occurring in high frequency in advanced cancer, it is an indicator of poor prognosis. Besides weight loss, patients experience a cluster of symptoms including anorexia, early satiety, and weakness. The 3 stages of cachexia include stages of precachexia, cachexia, and refractory cachexia. Refractory cachexia is associated with active catabolism or the presence of factors that make active management of weight loss no longer possible...
2017: Palliative Care
https://www.readbyqxmd.com/read/28825869/cancer-cachexia-cause-diagnosis-and-treatment
#9
Todd W Mattox
Patients with cancer frequently experience unintended weight loss due to gastrointestinal (GI) dysfunction caused by the malignancy or treatment of the malignancy. However, others may present with weight loss related to other symptoms not clearly associated with identifiable GI dysfunction such as anorexia and early satiety. Cancer cachexia (CC) is a multifactorial syndrome that is generally characterized by ongoing loss of skeletal muscle mass with or without fat loss, often accompanied by anorexia, weakness, and fatigue...
October 2017: Nutrition in Clinical Practice
https://www.readbyqxmd.com/read/28751550/novel-targeted-therapies-for-cancer-cachexia
#10
REVIEW
Josep M Argilés, Francisco Javier López-Soriano, Britta Stemmler, Sílvia Busquets
Anorexia and metabolic alterations are the main components of the cachectic syndrome. Glucose intolerance, fat depletion, muscle protein catabolism and other alterations are involved in the development of cancer cachexia, a multi-organ syndrome. Nutritional approach strategies are not satisfactory in reversing the cachectic syndrome. The aim of the present review is to deal with the recent therapeutic targeted approaches that have been designed to fight and counteract wasting in cancer patients. Indeed, some promising targeted therapeutic approaches include ghrelin agonists, selective androgen receptor agonists, β-blockers and antimyostatin peptides...
July 27, 2017: Biochemical Journal
https://www.readbyqxmd.com/read/28708669/the-role-of-hypothalamic-inflammation-the-hypothalamic-pituitary-adrenal-axis-and-serotonin-in-the-cancer-anorexia-cachexia-syndrome
#11
Klaske van Norren, Jvalini T Dwarkasing, Renger F Witkamp
PURPOSE OF REVIEW: In cancer patients, the development of cachexia (muscle wasting) is frequently aggravated by anorexia (loss of appetite). Their concurrence is often referred to as anorexia-cachexia syndrome. This review focusses on the recent evidence underlining hypothalamic inflammation as key driver of these processes. Special attention is given to the involvement of hypothalamic serotonin. RECENT FINDINGS: The anorexia-cachexia syndrome is directly associated with higher mortality in cancer patients...
July 13, 2017: Current Opinion in Clinical Nutrition and Metabolic Care
https://www.readbyqxmd.com/read/28691536/mabp1-for-the-treatment-of-colorectal-cancer
#12
Geraldine O'Sullivan Coyne, Mauricio Burotto
Inflammation is an established process in colorectal cancer development and a hallmark of progression, and pro-inflammatory cytokines have been implicated in the morbidity and functional compromise associated with malignancy. MABp1, described as a first-in-class true human antibody against interleukin-1α, has undergone clinical trial evaluation in a number of indications, recently completing late phase clinical trial testing under Fast Track designation for cancer anorexia-cachexia syndrome in colorectal cancer patients...
July 10, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28627024/the-applicability-of-a-weight-loss-grading-system-in-cancer-cachexia-a-longitudinal-analysis
#13
Ola Magne Vagnildhaug, David Blum, Andrew Wilcock, Peter Fayers, Florian Strasser, Vickie E Baracos, Marianne J Hjermstad, Stein Kaasa, Barry Laird, Tora S Solheim
BACKGROUND: A body mass index (BMI) adjusted weight loss grading system (WLGS) is related to survival in patients with cancer. The aim of this study was to examine the applicability of the WLGS by confirming its prognostic validity, evaluating its relationship to cachexia domains, and exploring its ability to predict cachexia progression. METHODS: An international, prospective observational study of patients with incurable cancer was conducted. For each patient, weight loss grade was scored 0-4...
June 18, 2017: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/28621564/the-emerging-role-of-anamorelin-hydrochloride-in-the-management-of-patients-with-cancer-anorexia-cachexia
#14
David C Currow, Richard Je Skipworth
Cancer cachexia affects many patients with advanced cancer. This multifactorial syndrome, which involves loss of muscle mass and body weight, profoundly affects patients' physical functioning and quality of life. Pharmacologic interventions that target weight loss and also improve patient-reported measures are required. Anamorelin hydrochloride is an oral ghrelin receptor agonist for the treatment of cancer anorexia-cachexia that stimulates release of growth hormone and insulin-like growth factor 1, and improves food intake and body weight...
August 2017: Future Oncology
https://www.readbyqxmd.com/read/28614627/a-randomized-phase-ii-feasibility-trial-of-a-multimodal-intervention-for-the-management-of-cachexia-in-lung-and-pancreatic-cancer
#15
Tora S Solheim, Barry J A Laird, Trude Rakel Balstad, Guro B Stene, Asta Bye, Neil Johns, Caroline H Pettersen, Marie Fallon, Peter Fayers, Kenneth Fearon, Stein Kaasa
BACKGROUND: Cancer cachexia is a syndrome of weight loss (including muscle and fat), anorexia, and decreased physical function. It has been suggested that the optimal treatment for cachexia should be a multimodal intervention. The primary aim of this study was to examine the feasibility and safety of a multimodal intervention (n-3 polyunsaturated fatty acid nutritional supplements, exercise, and anti-inflammatory medication: celecoxib) for cancer cachexia in patients with incurable lung or pancreatic cancer, undergoing chemotherapy...
June 14, 2017: Journal of Cachexia, Sarcopenia and Muscle
https://www.readbyqxmd.com/read/28579820/cannabis-and-intractable-chronic-pain-an-explorative-retrospective-analysis-of-italian-cohort-of-614-patients
#16
Guido Fanelli, Giuliano De Carolis, Claudio Leonardi, Adele Longobardi, Ennio Sarli, Massimo Allegri, Michael E Schatman
BACKGROUND: Despite growing interest in the therapeutic use of cannabis to manage chronic pain, only limited data that address these issues are available. In recent years, a number of nations have introduced specific laws to allow patients to use cannabis preparations to treat a variety of medical conditions. In 2015, the Italian government authorized the use of cannabis to treat several diseases, including chronic pain generally, spasticity in multiple sclerosis, cachexia and anorexia among AIDS and cancer patients, glaucoma, Tourette syndrome, and certain types of epilepsy...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/28573637/clinical-significance-of-androgen-secretion-disorders-in-men-with-a-malignancy
#17
REVIEW
Pawel J Wiechno, Grazyna M Poniatowska, Wojciech Michalski, Jakub Kucharz, Malgorzata Sadowska, Joanna Jonska-Gmyrek, Karol Nietupski, Joanna Rzymowska, Tomasz Demkow
Cancer and its treatment can lead in men to testosterone deficiency, accompanied by somatic and mental symptoms. Germ cell tumours and their treatment may disturb the pituitary-gonadal axis, hence leading to significant clinical abnormalities. In some prostate cancer patients, castration, temporary or permanent, is a desired therapeutic condition. Yet, it is burdened with various side effects of complex intensity and significance. Last but not least, patients in the terminal stage of a malignancy present with low testosterone concentrations as a part of anorexia-cachexia syndrome...
July 2017: Medical Oncology
https://www.readbyqxmd.com/read/28529141/z-505-hydrochloride-an-orally-active-ghrelin-agonist-attenuates-the-progression-of-cancer-cachexia-via-anabolic-hormones-in-colon-26-tumor-bearing-mice
#18
Makoto Yoshimura, Yoshihiro Shiomi, Yuta Ohira, Mineo Takei, Takao Tanaka
Cancer cachexia is a progressive wasting syndrome characterized by anorexia and weight loss, specifically muscle wasting and fat depletion. There is no therapeutic agent for treatment of this syndrome. We investigated the anti-cachexia effects of Z-505 hydrochloride (Z-505), a new oral growth hormone secretagogue receptor 1a (GHSR1a) agonist, using a mouse model of cancer cachexia. We performed a calcium flux assay in Chinese hamster ovary (CHO-K1) cells stably expressing human GHSR1a to quantify the agonistic activity of Z-505...
September 15, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28475119/oral-treatment-with-the-ghrelin-receptor-agonist-hm01-attenuates-cachexia-in-mice-bearing-colon-26-c26-tumors
#19
Fabienne O Villars, Claudio Pietra, Claudio Giuliano, Thomas A Lutz, Thomas Riediger
The gastrointestinal hormone ghrelin reduces energy expenditure and stimulates food intake. Ghrelin analogs are a possible treatment against cancer anorexia-cachexia syndrome (CACS). This study aimed to investigate whether oral treatment with the non-peptidergic ghrelin receptor agonist HM01 counteracts CACS in colon-26 (C26) tumor-bearing mice. The C26 tumor model is characterized by pronounced body weight (BW) loss and muscle wasting in the absence of severe anorexia. We analyzed the time course of BW loss, body composition, muscle mass, bone mineral density, and the cytokines interleukin-6 (IL-6) and macrophage-inhibitory cytokine-1 (MIC-1)...
May 5, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28471824/early-detection-of-sporadic-pancreatic-cancer-time-for-change
#20
Přemysl Frič, Aleksi Šedo, Jan Škrha, Petr Bušek, Martin Laclav, Pavel Škrha, Miroslav Zavoral
Sporadic pancreatic cancer amounts to ∼90% of all pancreatic cancers. It is a gloomy depressive disease and the most recalcitrant malignancy, with a very low 5-year survival (3-6%). At present, diagnostic methods are commonly applied, as used half a century ago, after the appearance of local and systemic symptoms (abdominal and back pain, cholestasis, painless jaundice, fatigue, anorexia, weight loss, anemia, peripheral phlebitis, and cachexia). Unfortunately, these symptoms are harbingers of an advanced disease...
August 2017: European Journal of Gastroenterology & Hepatology
keyword
keyword
103177
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"